The photos are not the myth. Pigment really does darken. The myths are everything built around the photos: that a visible tan proves safety, that a peptide is inherently mild, that a vial contains what the listing says, and that darker moles are a cosmetic side note rather than the single most serious problem with the compound.
Myth: a peptide is gentler than a drug
This one survives because the word sounds biological rather than pharmaceutical. Melanotan II is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone, and it acts on melanocortin receptors that are not confined to skin. That receptor family also touches vascular tone, sexual response and appetite, which is why the reported effects reach well past pigmentation. FDA’s published summary of potential significant safety risks for the substance names melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism, all taken from case reports in the literature. None of that is what people picture when they hear peptide.
Myth: the vial contains what the listing says
Laboratory work on this exact market says otherwise. Researchers who bought injectable tanning vials from three online shops and analyzed them by liquid chromatography with mass spectrometric detection found measured content well below the stated amount, roughly 43 to 88 percent of what was printed, with unidentified impurities of about 4 to 6 percent in material from two of the three sellers. A forensic laboratory examining a seized vial labeled as melanotan II reported purity around 30 percent. The FDA’s consumer guidance on counterfeit medicine and on evaluating online pharmacies exists because this failure mode is ordinary, not exceptional.
Myth: results in photos are the whole outcome
Any set of user-submitted before and after pictures is a survivor sample. The people whose experience ended in an emergency department, a biopsy, or a quiet decision to stop are not represented, and no reader can tell which frames sit next to a sunbed session or a bronzing lotion. Sociological work on image and performance enhancing drug communities describes exactly this dynamic, where practice and reputation are set by a small group of influential users writing an underground literature that no one audits.
Myth: darkened moles are just cosmetic
This is the misunderstanding with the highest cost. Melanocyte stimulation darkens existing nevi and can trigger new ones, and case reports describe crops of new pigmented lesions with atypical clinical and histological features in a man with a melanoma history who self-administered a synthetic alpha-MSH peptide. The label of the one approved drug in this receptor class treats the effect as expected rather than rare and recommends a twice yearly full body skin examination to keep pre-existing and new pigmented lesions under review. Outside that setting, nobody is doing the examination.
Myth: a tan from any source protects the skin
Induced pigment is not a substitute for sun protection, and a dermatology review of tanning summarized the direction of the evidence bluntly, with more risks and fewer benefits than the popular account suggests. Sunless products without sunscreen ingredients are required to carry a label warning stating that they do not protect against sunburn and that repeated tanning exposure may raise the risk of skin aging and skin cancer. Several published melanotan cases involve people using sunbeds during the same period, so the compound in practice accompanies UV exposure rather than replacing it.
Myth checklist
| Claim in circulation | What holds up | Evidence class |
|---|---|---|
| It is approved in some countries | No country has approved it for cosmetic tanning. Regulators have issued warnings instead | Regulatory statements |
| Research chemical labeling means lab grade quality | It is a legal position that places the seller outside drug regulation. It implies no injectable standard | Regulatory framework |
| Purity percentages on listings are meaningful | Independent analyses of purchased vials found content and purity far from the stated figures | Analytical chemistry studies |
| Side effects are limited to nausea and flushing | Case reports include rhabdomyolysis, renal infarction, priapism and melanoma | Case reports and series |
| Mole changes reverse when use stops | Sometimes. Reported outcomes include both regression and persistence | Individual case reports |
| Afamelanotide proves the class is safe for tanning | That product is approved only for a rare photosensitivity disorder, is implanted by a trained clinician, and carries its own monitoring warnings | Approved prescribing information |
Myth: buying from a slick website is the same as buying from a pharmacy
Presentation is the cheapest thing to fake. The questions worth asking are about accountability rather than design: which licensed pharmacy prepared a preparation, what lot it came from, and what qualifications sit with the provider behind it. A supervised route answers all three, and a supervised provider can also refuse a request outright, which is what happens with this compound at legitimate clinics. A gray market listing answers none of the three, because there is no pharmacy, no lot record, and no clinician attached to the transaction at all.
Myth: nothing else gives the same look
Topical dihydroxyacetone products give a comparable appearance through an entirely different mechanism, reacting with proteins in the outermost layer of dead skin cells rather than stimulating melanocytes. DHA is a listed color additive permitted for external application to the body, with restrictions that exclude the lips, other mucous membrane surfaces and the area of the eye. That is a regulated cosmetic category with an ingredient the agency has evaluated for that use, which is a description that cannot be applied to anything sold in an unmarked vial.
The lawful market that operates around all of this is straightforward to find. Ro, Hims and Hers, and Henry Meds run hormone and metabolic care behind a prescriber, while HealthRX maintains a peptide therapy library covering only products with an approval behind them. A tanning regimen built on melanotan II is absent from every one of them, which is exactly what a supply chain with a pharmacy and a lot number looks like from the buyer’s side.
Frequently asked questions
Why do so many sources use the word melanotan loosely?
Because the name covers more than one molecule. Dermatology literature has pointed out that melanotan I and melanotan II are distinct compounds, and that afamelanotide is a separate approved product. Sellers blur the three, so a claim attached to one is often repeated about another that has no such data behind it.
Does a good result from a friend mean the product is fine?
It means one person had a visible pigment change and reported no immediate problem. Content analyses show vials from different sellers vary widely, so two people buying the same named product may not be receiving the same material at all, and short term appearance says nothing about melanocytic changes.
Are the melanoma reports proof the compound causes cancer?
No, and the reviews that collect them say so. Case reports establish temporal association, not causation, and they cannot give a rate. What they do establish is that clinicians have repeatedly diagnosed melanoma in users, which is enough to make melanocyte stimulation without surveillance a poor trade.
Is injecting the risky part, or the molecule?
Both, separately. Unregulated product carries unknown identity, purity and sterility, so infection risk exists independent of pharmacology. The receptor effects add their own reported harms. Removing either problem would still leave the other one standing.
